SCHEMBL853104

SCHEMBL853104

CCOC(CNC)OCC

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.40
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.34
EPHX1 P07099 1/20 0.33
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12580534 0.87
SCHEMBL8315999 0.79 THRB (0.42) THRBLMNAKMT2AEPHX1
SCHEMBL4400004 0.78
SCHEMBL18508334 0.74
SCHEMBL2263311 0.74 KDM4E (0.41) THRBLMNAKMT2AEPHX1
SCHEMBL9508254 0.74 THRB (0.38) THRBLMNAKMT2AEPHX1
SCHEMBL28000400 0.74 THRB (0.38) THRBLMNAKMT2AEPHX1
SCHEMBL90517 0.74
SCHEMBL1137579 0.74 THRB (0.38) THRBLMNAKMT2AEPHX1
SCHEMBL10036684 0.72 THRB (0.36) THRBLMNAEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110845350-A Honokiol derivative and preparation method and application thereof 广东省禾基生物科技有限公司 2020-02-28 CN claimed
CN-110664795-A Water-soluble composition, preparation method and application thereof 广东省禾基生物科技有限公司 2020-01-10 CN claimed
CN-110615742-A Magnolol derivative and preparation method and application thereof 广东省禾基生物科技有限公司 2019-12-27 CN claimed
CN-119219823-A Adsorbent with heparin slow release function, preparation method thereof and blood perfusion device 泉州师范学院 2024-12-31 CN disclosed
CN-117088815-A Preparation method of methimazole 南京仁为医药科技有限公司 2023-11-21 CN disclosed
WO-2023200017-A1 NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS Prism BioLab Co., Ltd. (JP) 2023-10-19 WO disclosed
EP-3898630-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-05-10 EP disclosed
US-20230022724-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-26 US disclosed
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 US disclosed
US-20230013602-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 US disclosed
EP-3898631-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS HOFFMANN LA ROCHE (CH) 2023-01-18 EP disclosed
US-4397677-A HERBICIDES VELSICOL CHEMICAL CORPORATION (US) 1983-08-09 US disclosed
EP-0060697-A1 Heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-22 EP disclosed
EP-0060696-A1 Nitrogen heterocycles IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-09-22 EP disclosed
EP-0003619-B1 HETEROCYCLIC-SUBSTITUTED ANILIDE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, HERBICIDAL COMPOSITIONS CONTAINING THEM AND A METHOD OF CONTROLLING UNDESIRED PLANT GROWTH USING THEM SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1982-05-05 EP disclosed
EP-0047531-A1 2-(1,4-Benzodioxan-2-ylalkyl) imidazoles, their preparation and pharmaceutical compositions containing them SYNTEX (U.S.A.) INC. (US) 1982-03-17 EP disclosed
EP-0044185-A2 Imidazolidinone derivatives ELI LILLY AND COMPANY (US) 1982-01-20 EP disclosed
US-4302469-A 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants SYNTEX (U.S.A.) INC. (US) 1981-11-24 US disclosed
US-4279637-A Herbicidal N-substituted 4-imidazolin-2-ones VELSICOL CHEMICAL CORPORATION (US) 1981-07-21 US disclosed
EP-0003619-A2 Heterocyclic-substituted anilide derivatives, a process for their preparation, herbicidal compositions containing them and a method of controlling undesired plant growth using them SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1979-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022724-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, O60361, MYD88 THRB 3030/4885LMNA 3644/4885KMT2A 3310/4885
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, O60361, MYD88 THRB 3128/4885LMNA 3637/4885KMT2A 3307/4885
US-20230013602-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES IL4, RPS4Y1, RPS4X THRB 3081/4885LMNA 4067/4885KMT2A 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.